Drug Profile
Lonaprisan
Alternative Names: BAY86-5044; K-230211; ZK 230211; ZK-PRALatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class Antiprogestogens
- Mechanism of Action Progesterone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Dysmenorrhoea; Endometriosis
Most Recent Events
- 05 Apr 2011 Bayer Healthcare Pharmaceuticals completes a phase II trial in Breast cancer (metastatic disease) in Europe (NCT00555919)
- 14 Oct 2009 Discontinued - Preclinical for Dysmenorrhoea in Germany (PO)
- 14 Oct 2009 Discontinued - Preclinical for Dysmenorrhoea in USA (PO)